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ABSTRACT
Introduction: Pleural effusion is a common clinical
problem that can complicate many medical conditions.
Breathlessness is the most common symptom of
pleural effusion of any cause and the most common
reason for pleural drainage. However, improvement in
breathlessness following drainage of an effusion is
variable; some patients experience either no benefit or
a worsening of their breathlessness. The physiological
mechanisms underlying breathlessness in patients with
a pleural effusion are unclear and likely to be
multifactorial with patient-related and effusion-related
factors contributing. A comprehensive study of the
physiological and symptom responses to drainage of
pleural effusions may provide a clearer understanding
of these mechanisms, and may identify predictors of
benefit from drainage. The ability to identify those
patients whose breathlessness will (or will not)
improve after pleural fluid drainage can help avoid
unnecessary pleural drainage procedures, their
associated morbidities and costs. The PLeural Effusion
And Symptom Evaluation (PLEASE) study is a
prospective study to comprehensively evaluate factors
contributing to pleural effusion-related breathlessness.
Methods and analysis: The PLEASE study is a
single-centre prospective study of 150 patients with
symptomatic pleural effusions that require therapeutic
drainage. The study aims to identify key factors that
underlie breathlessness in patients with pleural
effusions and develop predictors of improvement in
breathlessness following effusion drainage. Participants
will undergo evaluation pre-effusion and post-effusion
drainage to assess their level of breathlessness at rest
and during exercise, respiratory and other physiological
responses as well as respiratory muscle mechanics.
Pre-drainage and post-drainage parameters will be
collected and compared to identify the key factors and
mechanisms that correlate with improvement in
breathlessness.
Ethics and dissemination: Approved by the Sir
Charles Gairdner Group Human Research Ethics
Committee (HREC number 2014-079). Registered with
the Australian New Zealand Clinical Trials Registry
(ACTRN12616000820404). Results will be published in
peer-reviewed journals and presented at scientific
meetings.
Trial registration number: ACTRN12616000820404;
Pre-results.
INTRODUCTION
Each year in Australia, pleural effusions are
found in around 60 000 patients. There are
more than 60 causes of pleural effusions,
with malignancy, infection and heart failure
being the most common. Breathlessness,
often disabling, is the most common
symptom in patients with pleural effusions.1
Pleural fluid drainage is often performed to
relieve breathlessness from recurrent (eg,
malignant) pleural effusions, but its effective-
ness is variable and unpredictable. In a pro-
spective study of patients with malignant
Strengths and limitations of this study
▪ First prospective study to comprehensively
assess breathlessness in patients with pleural
effusions.
▪ Validated assessment tools used can be per-
formed in the clinical setting.
▪ Developing predictors of improvement in breath-
lessness following pleural effusion drainage may
influence clinical practice.
▪ Not all of the vast number of potential contribut-
ing factors to breathlessness can be included in
the study.
▪ The methods of drainage and the volume of fluid
removed cannot be standardised, as the clinical
need of individual patients differs.
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pleural effusion (MPE) undergoing therapeutic pleural
fluid drainage, the change in the level of breathlessness
after drainage, assessed using a 100 mm Visual Analogue
Scale (VAS) score, varied widely; ∼15% of patients
reported no significant improvement, or worsening, of
their breathlessness after drainage.2
Breathlessness arising from pleural effusions is likely
to be multifactorial. The pathophysiological mechanism
of breathlessness from pleural effusion is unclear. The
severity of breathlessness often correlates poorly with the
size of the effusion. The modest improvement in forced
expiratory volume in 1 s (FEV1) (∼200 mL for every litre
of pleural fluid removed) and change in pulmonary
mechanics following thoracentesis3 4 do not explain the
degree of improvement in breathlessness reported by
many patients. Most prior studies have focused on spe-
cific aetiological factors in isolation,3 5–8 and their rele-
vance to the multifactorial nature of effusion-related
breathlessness is debated.
The ability to identify patients who are likely to
benefit from pleural fluid drainage would represent a
significant advance in clinical care. It may enable
patients who are unlikely to respond to avoid hospital
presentations, pleural interventions, and their associated
morbidity/mortality risks and healthcare costs. The
PLeural Effusion And Symptom Evaluation (PLEASE)
study will evaluate the factors contributing to effusion-
related breathlessness in a comprehensive manner.
METHODS AND ANALYSIS
The PLEASE study is a prospective study of 150 consecu-
tive patients with symptomatic pleural effusions treated
with pleural effusion drainage. The study aims to:
1. identify key factors that govern the symptom of
breathlessness in a patient with pleural effusion;
2. develop predictors of improvement in breathlessness
following pleural drainage.
The primary study hypothesis is that improvement in
breathlessness and functional exercise capacity from
pleural fluid drainage can be assessed using a combin-
ation of factors related to the patient and the effusion
(and its impact on lung and diaphragm mechanics).
Trial details are as per the PLEASE study trial protocol
V.3 (date 25 July 2015). A series of pre-drainage and
postdrainage measures will be performed on the partici-
pants to evaluate:
1. the severity of their breathlessness at rest and during
exercise,
2. their respiratory functions,
3. their diaphragmatic characteristics on pleural
ultrasonography.
The PLEASE study will assess changes in diaphragm
function following fluid drainage using advanced
imaging (eg, thoracic ultrasound). The potential import-
ance of mechanical function of the diaphragm and rib
cage in the physiological impairment of individuals with
benign asbestos-related pleural disease has been
highlighted previously.9 Specifically, drainage-related
changes in diaphragm shape and mechanics may play a
key role in the symptoms of breathlessness in patients
with pleural effusion.8 10
Participant screening and selection
The study aims to recruit 150 participants over a period
of 24 months at Sir Charles Gairdner Hospital, Perth,
Western Australia. Following on a recent internal audit,
this enrolment target can provide a representative cross-
section of pleural effusions of varying sizes, chronicity
and aetiology (eg, malignant, heart failure, hepatic
hydrothorax).
Patients presenting with a symptomatic pleural effusion
requiring therapeutic pleural drainage will be identified
as potential study participants by the treating clinicians
and screened according to specific criteria (see below).
Consecutive eligible patients will be offered participa-
tion in the study and a screening log will be maintained.
The study will be performed according to the
International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use (ICH) Good Clinical Practice (GCP) and
national and local regulatory and legal requirements.
The study doctor will obtain informed consent from the
patient prior to their participation in the study.
Inclusion criteria: Suitable participants are those with
symptomatic pleural effusion who require therapeutic
pleural drainage (by needle aspiration, indwelling
pleural catheter (IPC), intercostal catheter (ICC) includ-
ing those undergoing pleuroscopy) as part of standard
clinical management of the effusion and are able to
provide written informed consent.
Exclusion criteria include patients who:
1. are <18 years;
2. require urgent pleural drainage performed before
pre-drainage assessment tests can be completed;
3. are unable to perform lung function and/or exercise
tests, or are unable to comply with the protocol;
4. are pregnant or lactating.
Study measurements
1. Baseline assessment: All participants will be interviewed
and examined prior to pleural drainage (see figure 1).
i. Patient data: Demographics, comorbidities (eg,
chronic obstructive pulmonary disease (COPD),
heart disease), underlying cancer (type, stage,
treatment, etc) and relevant clinical data includ-
ing cardiopulmonary status (respiratory rate,
heart rate, blood pressure and oxygen saturation
by pulse oximetry) will be recorded.
ii. Pleural effusion characteristics: This will include (if
known) the aetiology of the effusion and the
details of any prior pleural procedures.
iii. Measurement of breathlessness: The severity of
breathlessness will be assessed using three instru-
ments: (a) VAS,11 12 (b) Dyspnea-12 (D-12)
Questionnaire13–15 and (c) Modified Borg 0–10
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scale.16 The VAS score is a validated measure of
breathlessness in MPE2 and has been used in
clinical trials involving MPE cohorts.11 17 The
participant places a mark on the 100 mm vertical
scale to indicate the severity of their breathless-
ness. A score of 0 mm indicates the most severe
breathlessness. The D-12 Questionnaire was
developed in people with chronic lung disease
and chronic heart failure15 and has demon-
strated validity and reliability in COPD, asthma,
interstitial lung disease and pulmonary arterial
hypertension.13–15 18 It consists of 12 questions
with physical (7 questions) and affective (5 ques-
tions) components. The D-12 Questionnaire
assesses current severity of dyspnoea and does
not depend on activity limitation. Each question
is scored on a 4-point scale (0–3 points), with a
total maximum score of 36 points indicating the
most severe level of dyspnoea. The modified
Borg 0–10 scale will be used to assess breathless-
ness at rest prior to the 6 min walk test and the
peak level of breathlessness evoked during the
test.16
iv. Measurement of functional exercise capacity:
Functional exercise capacity will be assessed using
the 6 min walk test. The test will be supervised by
trained operators and carried out in accordance
with international guidelines.19 The distance
walked (ie, 6 min walk test, 6 min walk distance
(6MWD)) will be expressed as an absolute dis-
tance (m) and as a percentage of the patient’s pre-
dicted 6MWD derived from a reference equation
developed locally in healthy individuals.20
v. Measurements of lung physiology: Spirometry and,
wherever possible, detailed lung functions,
including lung volumes and gas transfer mea-
surements, will be performed as per the
American Thoracic Society recommendations,21
provided that there are no contraindications.
vi. Measurements of diaphragmatic morphology and func-
tion: Pleural ultrasound will be employed to
assess diaphragm (1) shape—normal (domed),
flattened or inverted and (2) movement22—
normal, reduced or paradoxical.
vii. Radiological assessment of size of effusion: Effusions
will be graded based on their radiographic
appearance into five categories (where 0=no effu-
sion and 5 more than >75% of hemithorax) as
published by Light et al.23 The presence of other
radiographic abnormalities (eg, presence of
Figure 1 Trial entry, trial treatment and postprocedure care.
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mediastinal shift, trapped lung and fluid locula-
tions) will also be recorded.
2. Pleural drainage: The fluid will be removed at a con-
trolled rate to ensure patient safety as per inter-
national clinical guidelines.24 Data collected at the
time of pleural drainage will include:
i. Total volume and duration of pleural fluid drainage.
ii. Measurements of pleural pressure. In a subgroup of
patients, end-inspiratory and end-expiratory
pleural pressure measurements will be recorded
using a digital manometer (Compass; Mirador
Biomedical, Seattle, Washington, USA) at
opening pressure, after every 100 mL of drainage
(up to 1000 mL), and at closing pressure.
iii. Pleural fluid macroscopic appearance and biochem-
ical analysis (eg, pleural fluid pH and levels of
protein, lactate dehydrogenase and glucose).25
3. Repeat testing: The pre-drainage tests will be repeated
between 24 and 36 hours after completion of drainage.
Control/comparator
All participants will serve as their own control. The post-
drainage parameters will be compared with the pre-
drainage parameters in the same patient.
Standard care
All participants will receive standard care for their
respective conditions as determined by their attending
physicians. Participation in the PLEASE study will not
interfere with the administration of other treatments or
interventions necessary to manage the underlying condi-
tion. Pre-procedure workup, for example, blood tests and
chest imaging, will be decided by the managing clinician
(s), as is the choice of pleural drainage procedure. It is
expected that most patients will have fluid evacuated by
needle aspiration, chest tube or IPC insertion, performed
in accordance with standard practice and international
guidelines. Patients with pleural effusions undergoing
pleuroscopy and patients with an IPC already placed for
regular pleural fluid drainage may also participate.
Drainage procedures will be performed by the attend-
ing clinicians or their team members. The method of
drainage, volume (and speed) of fluid removal, monitor-
ing procedures during fluid evacuation, decisions to ter-
minate fluid evacuation during procedure (if needed)
and postprocedural care (including analgesia) are deter-
mined by the patients’ clinical team. Participants will be
monitored by standard continuous observations during
and after the pleural drainage procedure.
The participants will conclude their involvement in
the study with a clinic visit 2 weeks after the pleural
drainage procedure.
Statistical analysis plan
Descriptive statistics of baseline characteristics of patients
and measured responses will be provided. The magni-
tude and direction of the change between the predrai-
nage and post-drainage measurements (eg, responses in
breathlessness and functional capacity (6MWD)) will be
estimated using mean differences with 95% CIs pro-
vided. Formal statistical modelling will take two
approaches in order to (1) predict response in breath-
lessness and (2) model the mechanistic relationships
between responses in breathlessness and the changes in
pre-drainage and post-drainage measurements.
Multiple linear regression will be used to model and
predict the change in breathlessness after fluid drain-
age. Logistic regression, with receiver operating charac-
teristic (ROC) curve analyses, will be used to model the
dichotomous response of whether a clinically important
change in breathlessness has been achieved. These ana-
lyses will investigate the impact of baseline measure-
ments of variables included in the clinical data,
measurements of lung physiology and diaphragmatic
morphology (and function) and baseline demographics.
A prognostic index will be generated to identify patients
and patient characteristics that would predict a positive
outcome from pleural effusion drainage. To model the
mechanistic relationships between the change in mea-
surements from pre-procedure to post-procedure, corre-
lations and multiple linear regression analyses will be
used to describe associations between the breathlessness
variables and the changes in the aforementioned vari-
ables, as well as pleural effusion characteristics, dia-
phragmatic morphology and the total volume and
duration of pleural drainage.
While it is expected the missing data will be minimal,
standard imputation techniques will be used if necessary,
with regression analyses adjusted accordingly.
The sample size for this study was based on standard
regression modelling strategies26 and is deemed suffi-
cient given the number of predictors to be considered
in the modelling.
All data will be analysed using the R environment for
statistical computing (R: A language and environment
for statistical computing. R Foundation for Statistical
Computing. 2015. http://www.R-project.org/).
ETHICS AND DISSEMINATION
Data collection and management
Data will be entered into a secure study database and a
system of data validation checks will be implemented
and applied to the database. The accuracy of the data
will be verified by comparing study data to source docu-
ments. All procedures for the handling and analysis of
data will be conducted using GCP meeting ICH guide-
lines and the Australian Human Research Ethics
Committee for the handling and analysis of data for
clinical trials.
Safety reporting
All adverse events (AEs) occurring during the study
period will be documented and reported. A Data and
Safety Monitoring Committee, comprising three inde-
pendent members, will oversee the monitoring of all
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AEs. For each AE, the investigator will provide the onset,
end, intensity, treatment required, outcome, seriousness
and action taken. Serious AEs (SAEs) will be reported
immediately to the local ethics committee and the Data
and Safety Monitoring Committee using the Serious
Adverse Event Report Form including a documented
causal relationship assessment. An SAE is defined as any
AE that results in death; is life-threatening; results in per-
sistent or significant disability/incapacity; prolongs hos-
pitalisation by ≥24 hours; is deemed serious for any
other reason such that it is thought to jeopardise the
patient and may require medical or surgical intervention
to prevent one of the other outcomes listed in the above
SAE definitions.
Trial monitoring and oversight
A Trial Steering Committee, comprising the investigators
and trial coordinators, will be responsible for supervi-
sion of the trial in its entirety. It will be responsible for
ensuring completion of the trial to clinical and ethical
standards. The Data and Safety Monitoring Committee
will oversee the monitoring of AEs and the ethical
conduct of the study.
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